Profile data is unavailable for this security.
About the company
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
- Revenue in USD (TTM)0.00
- Net income in USD-60.04m
- Incorporated2019
- Employees6.00
- LocationLENZ Therapeutics Inc445 Marine View Ave Suite 320DEL MAR 92014United StatesUSA
- Phone+1 (858) 925-7000
- Fax+1 (302) 655-5049
- Websitehttps://graphitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics Inc | 32.96m | -175.80m | 803.40m | 586.00 | -- | 0.7337 | -- | 24.37 | -0.5999 | -0.5999 | 0.1125 | 3.71 | 0.0227 | -- | 0.958 | 56,250.85 | -12.10 | 6.08 | -12.95 | 6.67 | -- | -- | -533.32 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Capricor Therapeutics Inc | 23.23m | -34.11m | 808.91m | 101.00 | -- | 10.51 | -- | 34.82 | -1.06 | -1.06 | 0.7316 | 1.69 | 0.3571 | -- | 48.53 | 229,980.70 | -52.44 | -54.12 | -88.95 | -75.13 | -- | -- | -146.86 | -316.25 | -- | -- | 0.0471 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 823.70m | 58.00 | -- | 2.55 | -- | -- | -- | -- | -- | 8.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Bicara Therapeutics Inc | -100.00bn | -100.00bn | 870.14m | 32.00 | -- | 1.90 | -- | -- | -- | -- | -- | 9.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -81.05m | 893.05m | 40.00 | -- | 3.23 | -- | -- | -2.62 | -2.62 | 0.00 | 8.24 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Nuvation Bio Inc | 2.16m | -532.28m | 908.73m | 203.00 | -- | 1.81 | -- | 420.32 | -2.17 | -2.17 | 0.009 | 1.50 | 0.0036 | -- | 0.5936 | 42,392.16 | -88.53 | -16.27 | -94.44 | -16.65 | -32.38 | -- | -24,619.84 | -- | -- | -- | 0.0165 | -- | -- | -- | 27.25 | -- | -- | -- |
| Septerna Inc | 840.00 | -10.27k | 915.24m | 68.00 | -- | -- | -- | 1,089,573.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -60.04m | 943.83m | 6.00 | -- | 4.38 | -- | -- | -7.08 | -7.08 | 0.00 | 7.83 | 0.00 | -- | -- | 0.00 | -24.49 | -- | -25.55 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Zymeworks Inc | 62.20m | -113.67m | 946.15m | 294.00 | -- | 2.62 | -- | 15.21 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Upstream Bio Inc | -100.00bn | -100.00bn | 954.02m | 38.00 | -- | -- | -- | -- | -- | -- | -- | 4.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 957.15m | 587.00 | -- | 0.7658 | -- | 12.17 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Cogent Biosciences Inc | 0.00 | -242.30m | 982.87m | 164.00 | -- | 4.86 | -- | -- | -2.48 | -2.48 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -65.53 | -49.53 | -74.36 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| 89bio Inc | 0.00 | -288.96m | 985.34m | 70.00 | -- | 2.35 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.08bn | 37.00 | -- | 183.07 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.10bn | 593.00 | -- | 15.95 | -- | 5.74 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Data as of Nov 22 2024. Currency figures normalised to LENZ Therapeutics Inc's reporting currency: US Dollar USD
60.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 4.18m | 15.20% |
| Alpha Wave Global LPas of 30 Sep 2024 | 3.61m | 13.14% |
| Ridgeback Capital Management LLCas of 17 Jul 2024 | 1.95m | 7.10% |
| Point72 Asset Management LPas of 30 Sep 2024 | 1.88m | 6.85% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.11m | 4.03% |
| Sectoral Asset Management, Inc.as of 30 Sep 2024 | 977.25k | 3.55% |
| RTW Investments LPas of 30 Sep 2024 | 863.39k | 3.14% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 858.12k | 3.12% |
| Tang Capital Management LLCas of 30 Sep 2024 | 766.94k | 2.79% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 444.60k | 1.62% |
More ▼
Data from 17 Jul 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
